info@biomedres.us   +1 (720) 414-3554   600 Third Avenue, 2nd floor, New York - 10016, USA
ISSN: 2574 -1241

Review ArticleOpen Access

VEGF-Targeting Strategies against Diabetic Nephropathy: Obsolete or Still Promising?

Volume 2 - Issue 3

Katsuyuki Tanabe* and Jun Wada

  • Author Information Open or Close
    • Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Japan

    *Corresponding author: Katsuyuki Tanabe, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan, Tel: 81-86-235-7235; Email: tanabek@okayama-u.ac.jp

Received: January 30, 2018;   Published: February 13, 2018

DOI: 10.26717/BJSTR.2018.02.000758

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Vascular endothelial growth factor (VEGF)-A is well known to be involved in the pathogenesis of diabetic nephropathy. Although it may be a promising therapeutic target, recent evidence that anti-VEGF therapy induces renal thrombotic micro-angiopathy has tempered interest in its use. We discuss the necessary conditions for future VEGF-targeting therapy against diabetic nephropathy.

Keywords: Diabetic nephropathy; VEGF-A; Endothelial dysfunction; Podocytes

Abstract| Introduction| Conclusion| References|